Abstract
Cerebral cholesterol metabolism has been linked with production of amyloid peptide (Abeta) crucial in AD. The association between use of cholesterol-lowering drugs (statins) and AD disease is currently being intensely discussed. In this case-control study on elderly nondemented subjects, the authors provide the first evidence that statins in clinically relevant dosages indeed affect cerebral cholesterol metabolism. However, these changes were not associated with altered intrathecal secretion of Alzheimer Abeta.
Publication types
-
Comparative Study
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Aged
-
Alzheimer Disease / drug therapy
-
Alzheimer Disease / metabolism*
-
Amyloid beta-Peptides / cerebrospinal fluid
-
Amyloid beta-Peptides / metabolism*
-
Anticholesteremic Agents / pharmacology*
-
Anticholesteremic Agents / therapeutic use
-
Case-Control Studies
-
Cerebral Cortex / drug effects*
-
Cerebral Cortex / metabolism
-
Cholesterol / metabolism*
-
Female
-
Humans
-
Male
-
Middle Aged
-
Peptide Fragments / cerebrospinal fluid
-
Peptide Fragments / metabolism*
Substances
-
Amyloid beta-Peptides
-
Anticholesteremic Agents
-
Peptide Fragments
-
amyloid beta-protein (1-42)
-
Cholesterol